XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Segment Reporting (Tables)
9 Months Ended
Sep. 30, 2023
Segment Reporting  
Schedule of financial information by reporting segment

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2023

2022

2023

2022

(in thousands)

Net revenues:

    

    

    

    

    

    

    

    

 

Finished pharmaceutical products

$

176,366

$

117,120

$

455,242

$

353,789

API

 

4,190

3,009

11,048

10,175

Total net revenues

 

180,556

 

120,129

 

466,290

 

363,964

Gross profit (loss):

Finished pharmaceutical products

 

109,499

 

61,439

 

262,742

 

185,462

API

 

(1,096)

(2,929)

(7,761)

(7,770)

Total gross profit

 

108,403

 

58,510

 

254,981

 

177,692

Operating expenses

 

35,725

 

35,282

 

111,974

 

108,027

Income from operations

 

72,678

 

23,228

 

143,007

 

69,665

Non-operating income

 

(9,041)

 

(632)

 

(12,993)

 

5,115

Income before income taxes

$

63,637

$

22,596

$

130,014

$

74,780

Schedule of net revenues in the finished pharmaceutical products segment

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2023

2022

2023

2022

(in thousands)

Finished pharmaceutical products segment net revenues:

    

    

    

    

    

    

 

Glucagon

$

29,514

$

14,224

$

82,486

$

37,003

Primatene MIST®

24,834

18,359

64,837

62,030

Epinephrine

20,199

19,502

57,004

52,777

Lidocaine

15,522

12,621

43,174

39,253

Phytonadione

7,449

13,978

33,017

37,834

Enoxaparin

 

7,702

 

7,983

 

25,441

27,138

Naloxone

4,715

6,818

14,774

21,424

Other finished pharmaceutical products

 

37,730

 

23,635

 

105,808

 

76,330

Total finished pharmaceutical products net revenues

147,665

117,120

426,541

353,789

BAQSIMI®

28,701

28,701

Total finished pharmaceutical products segment net revenues

$

176,366

$

117,120

$

455,242

$

353,789

Schedule of depreciation and amortization expense by reporting segment

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2023

2022

2023

2022

(in thousands)

Depreciation and amortization expense

    

    

    

    

    

    

    

    

 

Finished pharmaceutical products

$

8,616

$

2,517

$

13,143

$

6,370

API

 

1,003

 

904

 

2,938

2,789

Total depreciation and amortization expense

$

9,619

$

3,421

$

16,081

$

9,159

Schedule of net revenues and carrying values of long-lived assets by geographic region

Net Revenue

Long-Lived Assets

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

September 30, 

December 31, 

2023

2022

2023

2022

2023

2022

(in thousands)

United States(1)

    

$

178,056

    

$

117,780

    

$

459,909

    

$

355,680

    

$

772,066

    

$

136,328

China

 

833

719

2,142

2,418

 

89,737

 

88,647

France

 

1,667

1,630

4,239

5,866

 

37,488

 

39,598

Total

$

180,556

$

120,129

$

466,290

$

363,964

$

899,291

$

264,573